| Alexandrov, Ludmil B |
University Of California, San Diego
United States |
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition |
5U01CA290479-03 |
|
Wendy Wang, Ph.D., M.Sc. |
| Anderson, Karen Sue |
Arizona State University-Tempe Campus
United States |
Southwest EDRN Clinical Validation Center for Head and Neck Cancer |
5U01CA281660-03 |
|
Wendy Wang, Ph.D., M.Sc. |
| Hecht, Stephen S |
University Of Minnesota
United States |
High resolution mass spectrometric profile analysis of carcinogen-DNA adducts in oral cells of cigarette smokers and squamous cell carcinoma of the head and neck |
5R01CA263084-05 |
PA-20-185 (Parent R01 Clinical Trial Not Allowed) |
Wendy Wang, Ph.D., M.Sc. |
| Labaer, Joshua |
Arizona State University-Tempe Campus
United States |
Multiplex In-Solution Protein Array (MISPA) for high throughput, quantitative, early profiling of pathogen-induced head and neck |
5R33CA281802-03 |
|
Wendy Wang, Ph.D., M.Sc. |
| Sidransky, David |
Johns Hopkins University
United States |
Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma |
5R01CA265975-04 |
|
Wendy Wang, Ph.D., M.Sc. |
| Herman, James G. |
University Of Pittsburgh At Pittsburgh
United States |
Optimizing Ultrasensitive DNA methylation detection for lung cancer and other malignancies |
5U2CCA271885-04 |
|
Wendy Wang, Ph.D., M.Sc. |
| Badve, Sunil S. |
Emory University
United States |
Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms |
5R01CA281932-02 |
|
Wendy Wang, Ph.D., M.Sc. |
| Mallery, Susan R |
Ohio State University
United States |
Formulation, Evaluation, and Phase 0 Trial of Nanoparticle Releasing Oral Thin Film for OSCC Chemoprevention |
5R01CA258757-04 |
|
Malgorzata Wojtowicz, M.D. |
| Tennis, Meredith A |
University Of Colorado Denver
United States |
Persistence and regression in lung premalignant lesions |
5R01CA289576-02 |
|
Malgorzata Wojtowicz, M.D. |
| Ondrey, Frank G. |
University Of Minnesota
United States |
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia |
5R01CA254270-04 |
PAR-21-035 (R01 Clinical Trial Required) |
Malgorzata Wojtowicz, M.D. |